← Back to Search

Sodium-glucose cotransporter 2 inhibitor

Exenatide for Type 2 Diabetes

Phase 4
Waitlist Available
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]
Awards & highlights

Study Summary

This trial will test a new way to measure EGP. It will screen subjects, measure EGP, then have them do a Double Tracer OGTT.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes] for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in EGP From Baseline to Post-oral Glucose Load.

Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: ExenatideActive Control1 Intervention
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Group II: DapagliflozinActive Control1 Intervention
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Group III: Exenatide and DapagliflozinActive Control1 Intervention
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Group IV: PlaceboPlacebo Group1 Intervention
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
452 Previous Clinical Trials
91,307 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,356 Previous Clinical Trials
4,314,959 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research mark a new era in medical science?

"Since 2007, Dapagliflozin has undergone a wealth of clinical trials. The first sponsored by CellTrans Inc. in 2007 involved 21 individuals. After the successful completion of this initial study, Dapagliflozin was approved for Phase 3 drug testing. As of now, there are 86 active studies being conducted in 242 different cities across 50 countries."

Answered by AI

For what purpose is Dapagliflozin typically prescribed?

"Dapagliflozin is used to treat patients that have not responded well to other forms of treatment. This pharmaceutical preparation can also be used in conjunction with diet and exercise."

Answered by AI

Are new participants being sought for this experiment?

"According to the latest information available on clinicaltrials.gov, this study is no longer recruiting patients. Although this particular trial is not ongoing, there are 914 other medical trials that are still looking for volunteers."

Answered by AI

Are there any prerequisites for joining this clinical trial?

"Eligible participants for this clinical trial must have type 2 diabetes mellitus, be within the ages of 18 and 70, and there are plans to recruit around 99 individuals in total."

Answered by AI

Is Dapagliflozin a danger to patients?

"Dapagliflozin has been approved, meaning it is safe to use."

Answered by AI

Are those over the age of 30 eligible for participation in this trial?

"In order to participate in this particular trial, patients must be aged between 18-70. Out of the 791 clinical trials that exist for people over the age of 65, this is one of 53 trials geared specifically towards those under 18 years old."

Answered by AI

How many people fit the requirements for this medical study?

"This study is not actively recruiting at the moment. It was initially posted on February 28th, 2018 and updated as recently as April 28th, 2022. However, if you are looking for other studies, 828 trials for patients with type 2 diabetes mellitus and 86 Dapagliflozin trials are still admitting patients."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What site did they apply to?
University Health System Texas Diabetic Institute
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

I need help controlling my diabetes.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

how long does it take?
PatientReceived 2+ prior treatments
Recent research and studies
Diabetes CareJournal
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
Alatrach, Mariam, Christina Agyin, Carolina Solis-Herrera, Olga Lavryneko, John Adams, Amalia Gastaldelli, Curtis Triplitt, Ralph A. DeFronzo, and Eugenio Cersosimo. 2022. “Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose”. Diabetes Care. American Diabetes Association. doi:10.2337/dc21-1798.
clinicaltrials.govStudy
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
2018. "Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03331289.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top